切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2016, Vol. 05 ›› Issue (03) : 158 -162. doi: 10.3877/cma.j.issn.2095-3232.2016.03.008

所属专题: 文献

临床研究

肝移植患者术后多重耐药鲍曼不动杆菌感染影响因素
浦燕萍1, 顾燕1, 杨富2, 王春光1, 彭文1, 方芳2, 钟林1,()   
  1. 1. 200080 上海交通大学附属第一人民医院肝移植中心
    2. 200080 上海交通大学附属第一人民医院护理部
  • 收稿日期:2016-03-15 出版日期:2016-06-10
  • 通信作者: 钟林

Influencing factors of multi-drug resistant Acinetobacter baumannii infection in patients after liver transplantation

Yanping Pu1, Yan Gu1, Fu Yang2, Chunguang Wang1, Wen Peng1, Fang Fang2, Lin Zhong1,()   

  1. 1. Liver Transplantation Center, Shanghai General Hospital, Shanghai 200080, China
    2. Department of Nursing, Shanghai General Hospital, Shanghai 200080, China
  • Received:2016-03-15 Published:2016-06-10
  • Corresponding author: Lin Zhong
  • About author:
    Corresponding author: Zhong Lin, Email:
引用本文:

浦燕萍, 顾燕, 杨富, 王春光, 彭文, 方芳, 钟林. 肝移植患者术后多重耐药鲍曼不动杆菌感染影响因素[J/OL]. 中华肝脏外科手术学电子杂志, 2016, 05(03): 158-162.

Yanping Pu, Yan Gu, Fu Yang, Chunguang Wang, Wen Peng, Fang Fang, Lin Zhong. Influencing factors of multi-drug resistant Acinetobacter baumannii infection in patients after liver transplantation[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2016, 05(03): 158-162.

目的

探讨肝移植患者术后鲍曼不动杆菌多重耐药状况及其感染的独立危险因素。

方法

回顾性分析2010年1月至2015年6月在上海交通大学附属第一人民医院行肝移植术的257例患者临床资料。所有患者均签署知情同意书,符合医学伦理学规定。其中25例为多重耐药鲍曼不动杆菌感染;男17例,女8例;年龄<50岁10例,≥50岁15例。采用浓度梯度法进行药物敏感性试验,复合纸法进行金属β-内酰胺酶检测,重复序列PCR和凝胶电泳进行细菌基因型检测。对多重耐药鲍曼不动杆菌进行耐药性分析,观察其耐药谱,以及基因型分布和发生感染时间,并分析其感染的影响因素。影响多重耐药鲍曼不动杆菌感染的单因素分析采用χ2检验,多因素分析采用logistic回归分析。

结果

多重耐药鲍曼不动杆菌的发生率为9.7%(25/257)。鲍曼不动杆菌菌株对氨基糖苷类、喹诺酮类、青霉素类、头孢菌素类和碳青霉烯类均表现为高耐药,耐药率100%,且96%(24/25)菌株金属β-内酰胺酶阳性。25株鲍曼不动杆菌可分为3个基因型,分别为B型18株,A型5株,C型2株。术后真菌培养阳性(OR=5.470,95%CI:1.402~21.333,P<0.05)和再次气管插管(OR=11.538,95%CI:2.228~59.742,P<0.05)是多重耐药鲍曼不动杆菌感染的独立危险因素。

结论

肝移植患者术后多重耐药鲍曼不动杆菌感染发生率高,对多种抗生素表现为高耐药,基因型以B型为主。术后真菌培养阳性和再次气管插管是其感染的独立危险因素。

Objective

To explore the multi-drug resistance condition and independent risk factors of Acinetobacter baumannii infection in patients after liver transplantation.

Methods

Clinical data of 257 patients who underwent liver transplantation in Shanghai General Hospital between January 2010 and June 2015 were retrospectively analyzed. The informed consents of all patients were obtained and the local ethical committee approval was received. Twenty-five patients were infected with multi-drug resistant Acinetobacter baumannii. Among the patients, 17 were males and 8 were females, 10 were younger than 50 years old and 15 were older or equal to 50 years old. Drug sensitive test was detected using concentration gradient method, metallo-beta-lactamase was detected using composite paper, and bacterial genotype was detected using repetitive sequence polymerase chain reaction (PCR) and gel electrophoresis. Drug resistance, drug-resistant spectrum, genotype distribution, infection time and influence factors of infection for multi-drug resistant Acinetobacter baumannii were observed and analyzed. Single-factor analysis of multi-drug resistant Acinetobacter baumannii was conducted using Chi-square test and multiple-factor analysis was conducted using logistic regression analysis.

Results

The incidence of multi-drug resistant Acinetobacter baumannii infection was 9.7%(25/257). Acinetobacter baumannii strains were highly resistant to aminoglycosides, quinolones, penicillins, cephalosporins and carbapenems, with the drug resistance of 100%. In addition, 96%(24/25) of the strains were metallo-beta-lactamase positive. Three genotypes were observed in the 25 strains of Acinetobacter baumannii: type B (n=18), type A (n=5) and type C (n=2). Positive postoperative fungal culture (OR=5.470, 95%CI: 1.402-21.333, P<0.05) and re-intubation (OR=11.538, 95%CI: 2.228-59.742, P<0.05) were the independent risk factors for multi-drug resistant Acinetobacter baumannii infection.

Conclusions

The incidence of multidrug-resistant Acinetobacter baumannii infection in patients after liver transplantation is high. Multidrug-resistant Acinetobacter baumannii is highly resistant to multiple antibiotics, and type B is the main genetype. Positive postoperative fungal culture and re-intubation are the independent risk factors for multi-drug resistant Acinetobacter baumannii infection.

表1 鲍曼不动杆菌对九种抗生素耐药性的检测
表2 多重耐药鲍曼不动杆菌感染的logistic多因素分析
[1]
Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen[J]. Clin Microbiol Rev, 2008, 21(3): 538-582.
[2]
Zarrilli R, Casillo R, Di Popolo A, et al. Molecular epidemiology of a clonal outbreak of multidrug-resistant Acinetobacter baumannii in a university hospital in Italy[J]. Clin Microbiol Infect, 2007, 13(5): 481-489.
[3]
de Oliveira JM, Lisboa Lde B. Hospital-acquired infections due to gram-negative bacteria[J]. N Engl J Med, 2010, 363(15): 1482-1483.
[4]
Raka L, Kalenó S, Bosnjak Z, et al. Molecular epidemiology of Acinetobacter baumannii in central intensive care unit in Kosova teaching hospital[J]. Braz J Infect Dis, 2009, 13(6): 408-413.
[5]
Rayes N, Seehofer D, Theruvath T, et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation--a randomized, double-blind trial[J]. Am J Transplant, 2005, 5(1): 125-130.
[6]
Reddy P, Zembower TR, Ison MG, et al. Carbapenem-resistant Acinetobacter baumannii infections after organ transplantation[J]. Transpl Infect Dis, 2010, 12(1): 87-93.
[7]
Ecker JA, Massire C, Hall TA, et al. Identification of Acinetobacter species and genotyping of Acinetobacter baumannii by multilocus PCR and mass spectrometry[J]. J Clin Microbiol, 2006, 44(8): 2921-2932.
[8]
Durante-Mangoni E, Zarrilli R. Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance[J]. Future Microbiol, 2011, 6(4): 407-422.
[9]
Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections[J]. Drugs, 2014, 74(12): 1315-1333.
[10]
Freire MP, Soares Oshiro IC, Bonazzi PR, et al. Surgical site infections in liver transplant recipients in the model for end-stage liver disease era: an analysis of the epidemiology, risk factors, and outcomes[J]. Liver Transpl, 2013, 19(9): 1011-1019.
[11]
Freire MP, Van Der Heijden IM, do Prado GV, et al. Polymyxin use as a risk factor for colonization or infection with polymyxin-resistant Acinetobacter baumannii after liver transplantation[J]. Transpl Infect Dis, 2014, 16(3): 369-378.
[12]
Bodro M, Sabé N, Tubau F, et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients[J]. Transplantation, 2013, 96(9): 843-849.
[13]
Ye QF, Zhao J, Wan QQ, et al. Frequency and clinical outcomes of ESKAPE bacteremia in solid organ transplantation and the risk factors for mortality[J]. Transpl Infect Dis, 2014, 16(5): 767-774.
[14]
Shi SH, Kong HS, Xu J, et al. Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients[J]. Transpl Infect Dis, 2009,11(5): 405-412.
[15]
Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004)[J]. Clin Microbiol Infect, 2006, 12(4): 315-321.
[16]
Souli M, Kontopidou FV, Koratzanis E, et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals[J]. Antimicrob Agents Chemother, 2006, 50(9): 3166-3169.
[17]
Falagas ME, Mourtzoukou EG, Polemis M, et al. Trends in antimicrobial resistance of Acinetobacter baumannii clinical isolates from hospitalised patients in Greece and treatment implications[J]. Clin Microbiol Infect, 2007, 13(8): 816-819.
[18]
Lima AL, Oliveira PR, Paula AP. Acinetobacter infection[J]. N Engl J Med, 2008, 358(26): 2846.
[19]
Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities[J]. Clin Infect Dis, 2006,42(5): 692-699.
[20]
Wareham DW, Bean DC, Khanna P, et al. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance[J]. Eur J Clin Microbiol Infect Dis, 2008, 27(7): 607-612.
[1] 农云洁, 黄小桂, 黄裕兰, 农恒荣. 超声在多重肺部感染诊断中的临床应用价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(09): 872-876.
[2] 李小飞, 刘洪莉, 石丘玲, 田静, 李莉, 漆洪波, 罗欣. 自然分娩产妇低强度聚焦超声子宫复旧治疗防治产后出血的前瞻性随机对照研究[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 534-539.
[3] 许月芳, 刘旺, 曾妙甜, 郭宇姝. 多粘菌素B和多粘菌素E治疗外科多重耐药菌感染临床疗效及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 700-703.
[4] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[5] 皮尔地瓦斯·麦麦提玉素甫, 李慧灵, 艾克拜尔·艾力, 李赞林, 王志, 克力木·阿不都热依木. 生物补片修补巨大复发性腹壁切口疝临床疗效分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 624-628.
[6] 顾熙, 徐子宇, 周澍, 张吴楼, 张业鹏, 林昊, 刘宗航, 嵇振岭, 郑立锋. 腹股沟疝腹膜前间隙无张力修补术后补片感染10 例报道[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 665-669.
[7] 臧宇, 姚胜, 朱新勇, 戎世捧, 田智超. 低温等离子射频消融治疗腹壁疝术后补片感染的临床效果[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 687-692.
[8] 杨闯, 马雪. 腹壁疝术后感染的危险因素分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 693-696.
[9] 胡菊英, 李银华, 洪兰, 王宏勇, 丁先军, 李承美, 谭心海. 儿童感染大叶性肺炎与支气管肺炎临床特征分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 813-816.
[10] 傅斌生, 冯啸, 杨卿, 曾凯宁, 姚嘉, 唐晖, 刘剑戎, 魏绪霞, 易慧敏, 易述红, 陈规划, 杨扬. 脂肪变性供肝在成人劈离式肝移植中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 789-794.
[11] 魏志鸿, 刘建勇, 吴小雅, 杨芳, 吕立志, 江艺, 蔡秋程. 肝移植术后急性移植物抗宿主病的诊治(附四例报告)[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 846-851.
[12] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[13] 丛黎, 马林, 陈旭, 李文文, 张亮亮, 周华亭. 改良CT严重指数联合炎症指标在重症急性胰腺炎患者胰腺感染预测及预后评估中的研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 432-436.
[14] 贾玲玲, 滕飞, 常键, 黄福, 刘剑萍. 心肺康复在各种疾病中应用的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 859-862.
[15] 颜世锐, 熊辉. 感染性心内膜炎合并急性肾损伤患者的危险因素探索及死亡风险预测[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 618-624.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?